Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Ping Chih Hsu; Shih Hong Li; Cheng Ta Yang

doi:10.1016/j.jtho.2018.06.022

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Ping Chih Hsu
, Shih Hong Li
, Cheng Ta Yang^*

^*Corresponding author for this work

Chung Gung Memorial Hospital
Chang Gung University

Research output: Contribution to journal › Journal Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	e227-e230
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	11
DOIs	https://doi.org/10.1016/j.jtho.2018.06.022
State	Published - 11 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.jtho.2018.06.022

Cite this

@article{6f6cd8628632402cb283720cdb02c263,

title = "Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis",

author = "Hsu, \{Ping Chih\} and Li, \{Shih Hong\} and Yang, \{Cheng Ta\}",

year = "2018",

month = nov,

doi = "10.1016/j.jtho.2018.06.022",

language = "英语",

volume = "13",

pages = "e227--e230",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "11",

}

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis. / Hsu, Ping Chih; Li, Shih Hong; Yang, Cheng Ta.
In: Journal of Thoracic Oncology, Vol. 13, No. 11, 11.2018, p. e227-e230.

Research output: Contribution to journal › Journal Letter › peer-review

TY - JOUR

T1 - Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

AU - Hsu, Ping Chih

AU - Li, Shih Hong

AU - Yang, Cheng Ta

PY - 2018/11

Y1 - 2018/11

UR - https://www.scopus.com/pages/publications/85055281995

U2 - 10.1016/j.jtho.2018.06.022

DO - 10.1016/j.jtho.2018.06.022

M3 - 快报

C2 - 30368415

AN - SCOPUS:85055281995

SN - 1556-0864

VL - 13

SP - e227-e230

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 11

ER -

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

UN SDGs

Access to Document

Other files and links

Cite this